Skip to main content
ARS Home » Pacific West Area » Albany, California » Western Regional Research Center » Healthy Processed Foods Research » Research » Publications at this Location » Publication #376520

Research Project: Prevention of Obesity Related Metabolic Diseases by Bioactive Components of Food Processing Waste Byproducts and Mitigation of Food Allergies

Location: Healthy Processed Foods Research

Title: Effect of beta-carotene status in microcapsules on its in vivo bioefficacy and in vitro bioaccessibility

item CHEN, XIAODONG - Jiangnan University
item LIANG, RONG - Jiangnan University
item ZHONG, FANG - Jiangnan University
item Yokoyama, Wallace - Wally

Submitted to: Food Hydrocolloids
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 3/9/2020
Publication Date: 3/9/2020
Citation: Chen, X., Liang, R., Zhong, F., Yokoyama, W.H. 2020. Effect of beta-carotene status in microcapsules on its in vivo bioefficacy and in vitro bioaccessibility. Food Hydrocolloids. 106. Article 105848.

Interpretive Summary: The effect of oil to increase the bioefficacy and bioavailability of different forms of beta-carotene was investigated in vitro and in a rat model. Crystalline beta-carotene was surprisingly found to have higher bioefficacy. Our investigation indicated that although solids are usually less soluble and available, bile salts were able to micellize the solid beta-carotene and increase their availability. Crystalline beta-carotene with an excipient oil in microcapsules was a promising method of effective delivery of high amounts of beta-carotene.

Technical Abstract: Sufficient loading capacity and high bioefficacy are both necessary if microencapsulated beta-carotene (BC) is supplemented to overcome Vitamin A deficiency. Four high BC loading (1.2%) microcapsules (BC melted in oil, MO; BC crystals dispersed in oil, CO; BC crystals embedded in wall material, CW; and BC crystals with excipient emulsion, CE) with same wall composition were prepared and their bioefficacy (BE) were compared by in vivo and in vitro tests. BE sequence (CE > CW > MO > CO) from in vivo study was found abnormal, which indicated higher efficacy of crystal BC over melted, excipient oil over oil as solvent. Morphology, particle size and micellization rate change during in vitro GI digestion were investigated to find the reason behind the abnormal. The results suggested that BC molecule could be released from its crystal and included into bile salt micelle with the shear provided by gastric and intestinal movements, the inclusion rate is crystal size dependent; the co-exiting oil would opposite the micellization rate if the oil-BC interaction affected either the diffusion of BC or the digestion of oil. The CE microcapsule had advantages in both factors and therefore resulted in the highest in vivo hepatic VAE, although the possible existence of equilibrium hepatic VAE level (800VAE µg/g liver) led to lower relative BE at excessive BC gavage dosage with effective BC microcapsules. The results from this study challenged the conventional positive concept of encapsulating amorphous BC, provided new insight into the design of effective BC microcapsules.